John J. Greisch Purchases 21,000 Shares of Catalent, Inc. (NYSE:CTLT) Stock

Catalent, Inc. (NYSE:CTLT) insider John J. Greisch purchased 21,000 shares of the business’s stock in a transaction dated Wednesday, August 30th. The shares were purchased at an average price of $50.24 per share, for a total transaction of $1,055,040.00. Following the purchase, the insider now owns 34,000 shares of the company’s stock, valued at approximately $1,708,160. The purchase was disclosed in a filing with the SEC, which is accessible through this link.

Catalent Trading Up 0.5 %

Catalent stock opened at $50.20 on Friday. The company has a quick ratio of 1.34, a current ratio of 1.84 and a debt-to-equity ratio of 0.91. Catalent, Inc. has a 52 week low of $31.45 and a 52 week high of $97.54. The company has a market capitalization of $9.05 billion, a price-to-earnings ratio of -38.62, a price-to-earnings-growth ratio of 5.96 and a beta of 1.22. The stock has a 50-day moving average price of $45.89 and a 200 day moving average price of $50.38.

Catalent (NYSE:CTLT) last released its earnings results on Tuesday, August 29th. The company reported $0.09 EPS for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.02). Catalent had a return on equity of 7.13% and a net margin of 0.93%. The firm had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.05 billion. During the same period last year, the firm earned $1.12 EPS. The company’s revenue for the quarter was down 15.6% compared to the same quarter last year. Sell-side analysts anticipate that Catalent, Inc. will post 0.83 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the company. JPMorgan Chase & Co. lowered Catalent from an “overweight” rating to a “neutral” rating and cut their price target for the company from $90.00 to $45.00 in a research note on Sunday, May 21st. Jefferies Financial Group lowered Catalent from a “buy” rating to a “hold” rating and cut their target price for the company from $45.00 to $44.00 in a research note on Wednesday, June 14th. Bank of America lifted their target price on Catalent from $39.00 to $46.00 and gave the company an “underperform” rating in a research note on Thursday. Deutsche Bank Aktiengesellschaft lifted their target price on Catalent from $37.00 to $45.00 and gave the company a “hold” rating in a research note on Tuesday, August 15th. Finally, Royal Bank of Canada lifted their target price on Catalent from $51.00 to $58.00 and gave the company an “outperform” rating in a research note on Wednesday. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and four have assigned a buy rating to the company. According to MarketBeat, Catalent presently has an average rating of “Hold” and a consensus target price of $60.50.

Institutional Investors Weigh In On Catalent

Several hedge funds have recently bought and sold shares of CTLT. Cetera Advisor Networks LLC boosted its position in Catalent by 7.1% in the 1st quarter. Cetera Advisor Networks LLC now owns 1,953 shares of the company’s stock worth $217,000 after purchasing an additional 130 shares in the last quarter. Private Advisor Group LLC boosted its position in Catalent by 18.0% in the 1st quarter. Private Advisor Group LLC now owns 2,957 shares of the company’s stock worth $328,000 after purchasing an additional 452 shares in the last quarter. Panagora Asset Management Inc. boosted its position in Catalent by 125.8% in the 1st quarter. Panagora Asset Management Inc. now owns 12,979 shares of the company’s stock worth $1,439,000 after purchasing an additional 7,231 shares in the last quarter. Yousif Capital Management LLC boosted its position in Catalent by 2.0% in the 1st quarter. Yousif Capital Management LLC now owns 24,561 shares of the company’s stock worth $2,724,000 after purchasing an additional 470 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its stake in shares of Catalent by 1.8% during the 1st quarter. Dimensional Fund Advisors LP now owns 991,019 shares of the company’s stock worth $109,904,000 after buying an additional 17,813 shares during the period.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.